Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of the Human Systemic Absorption of Sunscreen Ingredients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03582215
Recruitment Status : Completed
First Posted : July 10, 2018
Results First Posted : April 21, 2020
Last Update Posted : April 21, 2020
Sponsor:
Collaborator:
Spaulding Clinical Research LLC
Information provided by (Responsible Party):
Food and Drug Administration (FDA)

Brief Summary:

This study is designed to assess the systemic exposure and pharmacokinetics of sunscreen active ingredients (avobenzone, oxybenzone, ecamsule, octocrylene homosalate, octisalate and octinoxate) when sunscreen product is applied under maximal use conditions.

Part 1 is an open-label, randomized, 4-arm study in 24 healthy adult subjects with the primary objective to explore whether the active components (avobenzone, oxybenzone, ecamsule and octocrylene) of 4 sunscreen products (1 sunscreen product in each arm) are absorbed into the systemic circulation when a sunscreen product is applied under maximal use conditions.

One sunscreen product with the highest avobenzone exposure will be selected for the second part of the study. If there is no quantifiable exposure of avobenzone for any of the sunscreen products, the formulation with the highest oxybenzone exposure will be selected for Part 2. In addition, 3 new sunscreen products are included in Part 2.

Part 2 is an open label, 4-arm study in 48 healthy adult subjects with the primary objective to assess the pharmacokinetics of the active components in the selected product from Part 1 and 3 additional products with a combination of active ingredients (avobenzone, oxybenzone, octocrylene, ecamsule homosalate, octisalate and octinoxate as applicable/contained in the different products).


Condition or disease Intervention/treatment Phase
Systemic Exposure to Sunscreen Ingredients Drug: Part 1: Cream Drug: Part 1: Lotion Drug: Part 1: Spray 1 Drug: Part 1: Spray 2 Drug: Part 2: Lotion Drug: Part 2: Aerosol Spray Drug: Part 2: Nonaerosol Spray Drug: Part 2: Pump Spray Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Part 1 of the study has 4 parallel arms where 4 different sunscreen products will be studied. Part 2 of the study has 4 parallel arms where 4 sunscreen products (one from Part 1 and 3 new sunscreen products) will be studied.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Assessment of the Human Systemic Absorption of Sunscreen Ingredients
Actual Study Start Date : July 18, 2018
Actual Primary Completion Date : February 18, 2019
Actual Study Completion Date : February 18, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sun Exposure

Arm Intervention/treatment
Experimental: Part 1: Cream

Part 1: Cream

Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule

Drug: Part 1: Cream
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Octocrylene
  • Ecamsule

Experimental: Part 1: Lotion

Part 1: Lotion

Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene

Drug: Part 1: Lotion
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Oxybenzone
  • Octocrylene

Experimental: Part 1: Spray 1

Part 1: Spray 1

Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate

Drug: Part 1: Spray 1
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Homosalate
  • Octisalate
  • Octocrylene
  • Oxybenzone

Experimental: Part 1: Spray 2

Part 1: Spray 2

Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene

Drug: Part 1: Spray 2
Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Oxybenzone
  • Octocrylene

Experimental: Part 2: Lotion

Part 2: Lotion

Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene

Drug: Part 2: Lotion
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Oxybenzone
  • Octocrylene

Experimental: Part 2: Aerosol Spray

Part 2: Aerosol Spray

Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate

Drug: Part 2: Aerosol Spray
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Oxybenzone
  • Octocrylene
  • Homosalate
  • Octisalate

Experimental: Part 2: Nonaerosol Spray

Part 2: Nonaerosol Spray

Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate

Drug: Part 2: Nonaerosol Spray
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Octocrylene
  • Homosalate
  • Octisalate
  • Octinoxate

Experimental: Part 2: Pump Spray

Part 2: Pump Spray

Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate

Drug: Part 2: Pump Spray
Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Other Names:
  • Avobenzone
  • Homosalate
  • Octisalate
  • Octinoxate




Primary Outcome Measures :
  1. Avobenzone Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2 ]
    Maximum concentration (observed peak drug concentration) (Cmax)


Secondary Outcome Measures :
  1. Oxybenzone Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2 ]
    Maximum concentration (observed peak drug concentration) (Cmax)

  2. Octocrylene Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1; same time points and 216, 312, and 480 h for Part 2 ]
    Maximum concentration (observed peak drug concentration) (Cmax)

  3. Ecamsule Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, and 144 h for Part 1 ]
    Maximum concentration (observed peak drug concentration) (Cmax)

  4. Homosalate Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2 ]
    Maximum concentration (observed peak drug concentration) (Cmax)

  5. Octisalate Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2 ]
    Maximum concentration (observed peak drug concentration) (Cmax)

  6. Octinoxate Maximum Concentration [ Time Frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 9, 10, 12, 14, 23, 28, 33, 47, 52, 57, 71, 73, 74, 76, 78, 81, 82, 84, 86, 95, 120, 144, 216, 312, and 480 h for Part 2 ]
    Maximum concentration (observed peak drug concentration) (Cmax)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Subjects who meet all of the following inclusion criteria will be eligible to participate in the study:

  1. Subject signs an institutional review board (IRB) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization) before any study related procedures are performed.
  2. Subject is a healthy man or woman, 18 to 60 years of age, inclusive, who has a body mass index of 18.5 to 29.9 kg/m2, inclusive, at Screening.
  3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead electrocardiogram (ECG) results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).
  4. Subject must have a negative test result for alcohol and drugs of abuse at screening and Check-in (Day 0).
  5. Subject has no known or suspected allergies or sensitivities to any components of the sunscreen formulation.
  6. Female subjects must be of non-childbearing potential or, if they are of childbearing potential, they must: 1) have been strictly abstinent for 1 month before Check in (Day 0) and agree to remain strictly abstinent for the duration of the study and for at least 1 month after the last application of study drug; OR 2) be practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from at least 1 month before Check in (Day 0) until at least 1 month after the last application of study drug.
  7. Female subjects must not be pregnant or lactating before enrollment in the study.
  8. Male subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from at least 1 month before Check in (Day 0) until at least 1 month after the last application of study drug.
  9. Subject is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.

Note: subjects with any skin type or skin pigment type may be eligible for the study.

Subjects who meet any of the following exclusion criteria will not be eligible to participate in the study:

  1. Subject has broken, irritated, or unhealed skin.
  2. Subject has an active sunburn.
  3. Subject has used a tanning bed in the previous 4 weeks.
  4. Subject has known skin or autoimmune disease(s).
  5. Subject is anemic or has any chronic condition(s) that may impact blood sample collection.
  6. Subject has any underlying disease or surgical or medical condition (e.g., cancer, human immunodeficiency virus [HIV], severe hepatic or renal impairment) that could put the subject at risk or would normally prevent participation in a clinical study.
  7. Subject has known or suspected allergies or sensitivities to any components of the sunscreen formulation.
  8. Subject has clinical laboratory test results (hematology and serum chemistry) at Screening that are outside the reference ranges provided by the clinical laboratory and considered clinically significant by the investigator.
  9. Subject has a positive test result at Screening for HIV 1 or 2 antibody, hepatitis C virus antibodies, or hepatitis B surface antigen.
  10. Subject is unable or unwilling to undergo multiple venipunctures for blood sample collection because of poor tolerability or poor venous access.
  11. Subject has received or applied the topical sunscreen formulations used in the current study, or any other product containing the active ingredients of the topical sunscreen formulations used in the current study, within 7 days before Check in (Day 0).
  12. Subject has used any personal care product(s) containing any active sunscreen ingredient, such sunscreen products, hand or body moisturizing lotion, makeup or foundation, lip balm, or lipstick, within 7 days before Check in (Day 0).
  13. Subject is unable or unwilling to tolerate the scent of sunscreen for the duration of the treatment period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03582215


Locations
Layout table for location information
United States, Wisconsin
Spaulding Clinical Research
West Bend, Wisconsin, United States, 53095
Sponsors and Collaborators
Food and Drug Administration (FDA)
Spaulding Clinical Research LLC
Investigators
Layout table for investigator information
Principal Investigator: Carlos R Sanabria, MD Spaulding Clinical Research LLC
  Study Documents (Full-Text)

Documents provided by Food and Drug Administration (FDA):
Study Protocol  [PDF] December 13, 2018
Statistical Analysis Plan  [PDF] November 20, 2018

Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Deidentified participant data for Part 1 is accessible under Supplement 3
Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Deidentified participant data for Part 2 is accessible under Supplement 3

Publications of Results:
Layout table for additonal information
Responsible Party: Food and Drug Administration (FDA)
ClinicalTrials.gov Identifier: NCT03582215    
Other Study ID Numbers: SCR-005
First Posted: July 10, 2018    Key Record Dates
Results First Posted: April 21, 2020
Last Update Posted: April 21, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified data from the clinical study was included as part of supplementary materials for both publications
Supporting Materials: Study Protocol
Clinical Study Report (CSR)
Time Frame: Jan 2020 - supplementary materials included with publications
Access Criteria:

Access to JAMA. De-identified data has been included under supplement 3 for Part 1 (Matta et al, 2019 JAMA) and Part 2 (Matta et al, 2020, JAMA) of this clinical study

Part 1 study data:

https://cdn.jamanetwork.com/ama/content_public/journal/jama/938034/jpc190002supp3_prod.xlsx


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Food and Drug Administration (FDA):
Sunscreen
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Salicylates
Avobenzone
Homosalate
Oxybenzone
2-ethylhexyl salicylate
Octylmethoxycinnamate
Sunscreening Agents
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Dermatologic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action